IP Library Granted Patent US 6,995,238
Granted Patent B2
US 6,995,238 · App. 10/183,410 · Granted Feb 7, 2006

Cyclopeptide derivatives

Assignee: Biomet Deutchland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,995,238
App. No.
10/183,410
Granted
Feb 7, 2006
Kind
B2
Abstract

Disclosed herein is a process for promoting the integration of a biocompatible device or implant into a tissue of a subject. The process comprises covalently bonding to the surface of the device or implant a compound of the formula I R-Q-X  I wherein R is cyclo-(Arg-Gly-Asp-Z), and wherein Q, X and Z are as defined herein.

Claims (68)

1. A process for promoting the integration of a device which is useful as an implant or of a biocompatible device into tissue which contains integrin bearing cells, said process comprising covalently bonding to the surface of said device which is useful as an implant or of said biocompatible device a compound of the following formula I

R-Q-X  I

in which

R is cyclo-(Arg-Gly-Asp-Z), where Z is bonded via a side chain to Q, or if Q is absent, to X,

Q is absent, or is —(CO—R 1 —NH—) m , —(NH—R 1 —CO—) m , —(CO—R 1 —CO—) m , —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) n ,

—(NH—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —CO—) n ,

—(NH—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 —CO—) n or

—(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) n —(CO—R 1 —NH—) m ,

X is —CO—CH═CH 2 , —CO—C(CH 3 )═CH 2 , —NH—CH═CH 2 , —NH—C(CH 3 )═CH 2 or —NH—(CH 2 ) p —SR 10 ,

Z is in each case independently of one another an amino acid residue or a di- or tripeptide residue, where the amino acids independently of one another are selected from a group consisting of Ala, Asn, Asp, Ag, Cys, Gln, Glu, Gly, His, Homo-Phe, Ile, Leu, Lys, Met, Phe, Phg, Pro, Ser, Thr, Trp, Tyr, Val and M,

wherein said amino acids can be derivatized, and the amino acid residues are linked to one another in peptide fashion via the α-amino- and α-carboxyl groups, and

where M is always present,

M is a residue of NH(R 8 )—CH(R 3 )—COOH,

R 1 is absent or is R 2 , R 9 , R 2 —R 9 —R 2 , or phenylene which is unsubstituted or mono- or disubstituted by R 5 , where the chain length of R 5 is in each case independent of one another,

R 2 is alkylene having 1-10 C atoms, where 1 or 2 methylene groups can be replaced by S, —CH═CH— or —C≡C—,

R 3 is —R 5 —R 4 , —R 6 —R 4 or —R 7 —R 4 ,

R 4 is OH, NH 2 , SH or COOH,

R 5 is alkylene having 1-6 C atoms,

R 6 is alkylenephenylene having 7-14 C atoms,

R 7 is alkylenephenylalkylene having 8-15 C atoms,

R 8 is H, A or alkylenephenyl having 7-12 C atoms,

R 9 is cycloalkylene having 3-7 C atoms,

R 10 is H or an S protective group,

A is alkyl having 1-6 C atoms,

Hal is F, Cl, Br or I

m and n in each case independently of one another are 0, 1, 2 or 3 and

p is 1, 2, or 3,

where each optically active amino acid or amino acid derivative that is present is in either the D or L form; or

a salt thereof,

thereby producing a coated device, and

bringing said coated device into contact with tissue.

2. A process according to claim 1 , wherein said compound is:

a) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —CO—CH 2 CH 2 CO—NH—CH 2 CH 2 —SH)) or a physiologically acceptable salt thereof,

b) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —CO—CH 2 CH 2 CO—NH—CH 2 CH 2 —SH)-Gly) or a physiologically acceptable salt thereof;

c) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —CO—(CH 2 ) 5 —NH—CO—CH═CH 2 )) or a physiologically acceptable salt thereof;

d) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —CO—(CH 2 ) 5 —NH—CO—CH═CH 2 )) or a physiologically acceptable salt thereof;

e) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—CO—(CH 2 ) 5 —NH—CO—CH═CH 2 )) or a physiologically acceptable salt thereof; or

f) cyclo-(Arg-Gly-Asp-D-Phe-Lys(N ε —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH) 2 —CO—(CH 2 ) 5 —NH—CO—CH═CH 2 )) or a physiologically acceptable salt thereof.

3. A process according to claim 1 , wherein R 1 is alkylene having 1-10 C atoms.

4. A process according to claim 1 , wherein Q is a 6-aminohexanoic acid radical, a succinyl radical, —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH)—, —(CO—CH—O—CH 2 —O—CH 2 CH 2 —NH—)CO—(CH 2 ) 5 —NH—, —(CO—(CH 2 ) 5 —NH) 2 —, or —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) 2 CO—(CH 2 ) 5 —NH—.

5. A process according to claim 1 wherein M is Dap (diamino propionic acid), Ser, Cys, Asp, D-Asp, Dab (diamino butyric acid), homoserine, homocysteine, Glu, D-Glu, Thr, Orn, Lys, D-Lys, 4-aminomethyl-Phe or 4-aminomethyl-D-Phe.

6. A process according to claim 1 , wherein Z is M.

7. A process according to claim 1 , wherein —R 6 —R 4 is 2,3- or 4-hydroxybenzyl, 2-, 3- or 4-aminobenzyl, 2-, 3- or 4-mercaptobenzyl, 2-, 3- or 4-carboxybenzyl, 2-, 3- or 4-hydroxyphenethyl, 2-, 3- or 4-aminophenethyl, 2-, 3- or 4-mercaptophenethyl, or 2-, 3- or 4-carboxyphenethyl.

8. A process according to claim 1 , wherein Z is D-Phe-M, Phe-M, D-Trp-M, Trp-M, D-Tyr-M, Tyr-M, D-Phg-M, Phg-M, D-homo-Phe-M, homo-Phe-M or D-Phe-Lys-Gly.

9. A compound according to claim 1 , wherein Z is D-Phe-M, Phe-M, D-Trp-M, Trp-M, D-Tyr-M, Tyr-M, D-Phg-M, Phg-M, D-homo-Phe-M, homo-Phe-M or D-Phe-Lys-Gly and X is —CO—CH═CH 2 , —NH—CH═CH 2 , or —NH—(CH 2 ) p —SH.

10. A process according to claim 1 , wherein

Z is D-Phe-M, Phe-M, D-Trp-M, Trp-M, D-Tyr-M, Tyr-M, D-Phg-M, Phg-M, D-homo-Phe-M, homo-Phe-M or D-Phe-Lys-Gly and

X is —CO—CH═CH 2 or —NH—(CH 2 ) p —SH.

11. A process according to claim 1 , wherein

Z is D-Phe-M, Phe-M, D-Trp-M, Trp-M, D-Tyr-M, Tyr-M, D-Phg-M, Phg-M, D-homo-Phe-M, homo-Phe-M or D-Phe-Lys-Gly

X is —CO—CH═CH 2 , —NH—CH═CH 2 or —NH—(CH 2 ) p —SH and

R1 is alkylene having 1-10 C atoms wherein 1 or 2 methylene groups can be replaced by S, —CH═CH— or —C≡C—.

12. A process according to claim 1 , wherein

R is cyclo-(Arg-Gly-Asp-D-Phe-M), and

X is —CO—CH═CH 2 , —NH—CH═CH 2 or —NH—(CH 2 ) p —SH.

13. A process according to claim 1 , wherein

R is cyclo-(Arg-Gly-Asp-D-Phe-M) or,

Q is —CO—(CH 2 ) 5 —NH, —CO—(CH 2 ) 2 —CO—, —CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—, —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) 2 —CO—(CH 2 ) 5 —NH—, —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) 1 —CO—(CH 2 ) 5 —NH— or —(CO—(CH 2 ) 5 —NH) 2 —,

X is —CO—CH═CH 2 , —NH—CH═CH 2 or —NH—(CH 2 ) p —SH, and

R1 is alkylene having 1-10C atoms wherein 1 or 2 methylene groups can be replaced by S, —CH═CH— or —C≡C—.

14. A process according to claim 1 , wherein

Z is D-Phe-Lys-Gly, and

X is —CO—CH═CH 2 , —NH—CH═CH 2 or —NH—(CH 2 ) p —SH.

15. A process according to claim 14 , wherein

Z is D-Phe-Lys-Gly,

Q is —CO—(CH 2 ) 5 —NH, —CO—(CH 2 ) 2 —CO—, —CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—, —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) 2 —CO—(CH 2 ) 5 —NH—, —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—)1-CO—(CH 2 ) 5 —NH— or —(CO—(CH 2 ) 5 —NH) 2 —,

X is —CO—CH═CH 2 , —NH—CH═CH 2 or —NH—(CH 2 ) p —SH, and

R 1 is alkylene having 1-10C atoms wherein 1 or 2 methylene groups can be replaced by S, —CH═CH— or —C≡C—.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2004
From: MERCK PATENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
To: BIOMET DEUTSCHLAND GMBH
Reel/Frame 014797/0110 →
Priority Claims (1)
DE 197 55 800 · Dec 16, 1997 · national
Continuity (2)
Division 0958157500
Related Publication 20020198142A1 · Dec 26, 2002